Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $34.6152W HIGH $95.49
Volume
1.78 M
Value Traded
75.35 M
Short % Float
6.97%
-5.37%Week
-26.49%1 Month
-20.5%3 Month
-6.75%6 Month
-0.85%5 Year
-97.44%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.56 B
EPS (TTM)
-2.10
P/E Ratio
-
Ent. Value
7.64 B
Total Shares
140.92 M
Float Shares
132.97 M
Insiders
5.87%
Institutions
83.05%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ARWR Catalyst Timeline
Dated clinical, regulatory and corporate events for Arrowhead Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Arrowhead Pharmaceuticals, Inc.
417Total events
16Upcoming
104Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Timing GuidancePlozasiranApprovedPresentation
FDA grants plozasiran entry in STAR pilot program for upcoming sNDA in sHTG
severe hypertriglyceridemiasource ↗
▲Topline ReadoutARO-DIMERPAClinical Data
Interim topline data from Phase 1/2a trial of ARO-DIMER-PA in mixed hyperlipidemia
mixed hyperlipidemiasource ↗
▲PK PD DataARO-DIMERPAClinical Data
Single dose reductions in PCSK9, APOC3, LDL-C, TG, non-HDL, ApoB
mixed hyperlipidemiasource ↗
▲Safety Data UpdateARO-DIMERPAClinical Data
Interim safety data: single dose escalation completed through 400 mg, no drug-related SAEs
mixed hyperlipidemiasource ↗
●Enrollment UpdateARO-DIMERPATrial
Single dose escalation completed through 400 mg; study ongoing for multiple doses
mixed hyperlipidemiasource ↗
●Quarterly UpdatePlozasiranApprovedCorporate
Conference call and webcast to discuss SHASTA-3 and SHASTA-4 results
severe hypertriglyceridemiasource ↗
●Oral PresentationPlozasiranApprovedPresentation
Arrowhead to host conference call and webcast to discuss SHASTA-3 and SHASTA-4 results
severe hypertriglyceridemiasource ↗
▲Oral PresentationPlozasiranApprovedPresentation
Presentation of Phase 3 SHASTA-3 and SHASTA-4 results at ESC Congress 2026
severe hypertriglyceridemiasource ↗
▲Topline ReadoutPlozasiranApprovedClinical Data
Topline results for SHASTA-3 announced
severe hypertriglyceridemiasource ↗
▲Primary Endpoint MetPlozasiranApprovedClinical Data
SHASTA-3 met primary and all prespecified secondary endpoints with 79% median TG reduction at Month 12
severe hypertriglyceridemiasource ↗
▲Secondary Endpoint DataPlozasiranApprovedClinical Data
All prespecified secondary endpoints met in SHASTA-3 and SHASTA-4
severe hypertriglyceridemiasource ↗
▲Full ResultsPlozasiranApprovedClinical Data
Detailed results from SHASTA-3 and SHASTA-4 presented at ESC Congress 2026
severe hypertriglyceridemiasource ↗
▲Pooled AnalysisPlozasiranApprovedClinical Data
Prespecified pooled analysis showed 78% reduction in AP events versus placebo
severe hypertriglyceridemiasource ↗
▲Subgroup AnalysisPlozasiranApprovedClinical Data
In patients with TG above 880 mg/dL and prior AP history, 100% reduction in AP events versus placebo
severe hypertriglyceridemiasource ↗
▲Safety Data UpdatePlozasiranApprovedClinical Data
Plozasiran demonstrated favorable safety and tolerability profile with TEAEs similar to placebo
severe hypertriglyceridemiasource ↗
◆Late-BreakerPlozasiranApprovedPresentation
Detailed SHASTA-3/SHASTA-4 results to be presented as HOT LINE Late Breaker at ESC Congress
severe hypertriglyceridemia (sHTG)source ↗
▲Product LaunchREDEMPLOApprovedPost-Market
REDEMPLO listed in Lauer-Taxe database in Germany
familial chylomicronaemia syndrome (FCS)source ↗
▲PRV GrantedPlozasiranApprovedDesignation
Purchase of FDA Priority Review Voucher announced
severe hypertriglyceridemiasource ↗
▲Topline ReadoutPlozasiranApprovedClinical Data
Topline results announced for Phase 3 SHASTA-3 and SHASTA-4 of plozasiran in sHTG
severe hypertriglyceridemia (sHTG)source ↗
▲Primary Endpoint MetPlozasiranApprovedClinical Data
SHASTA-3 and SHASTA-4 met primary endpoint of triglyceride reduction versus placebo
severe hypertriglyceridemia (sHTG)source ↗
▲Enrollment CompletezodasiranTrial
Enrollment completed in global Phase 3 YOSEMITE trial of zodasiran in HoFH
homozygous familial hypercholesterolemia (HoFH)source ↗
▲EU ApprovalREDEMPLOApprovedEx-US Regulatory
European Commission granted marketing authorization for REDEMPLO in FCS
familial chylomicronemia syndrome (FCS)source ↗
▲FDA ApprovalREDEMPLOApprovedFDA Decision
Australian TGA approved REDEMPLO for FCS
familial chylomicronemia syndrome (FCS)source ↗
▲Partnership / LicenseARO-PNPLA3Corporate
Exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3
metabolic dysfunction-associated steatohepatitis (MASH)source ↗
▲Milestone PaymentARO-PNPLA3Corporate
Madrigal made $25 million upfront payment to Arrowhead
metabolic dysfunction-associated steatohepatitis (MASH)source ↗
▲PK PD DataARO-PNPLA3Clinical Data
ARO-PNPLA3 achieved dose-dependent mean reduction in liver fat up to 40% in Phase 1 SAD study
metabolic dysfunction-associated steatohepatitis (MASH)source ↗
▲Enrollment CompletezodasiranTrial
Completed enrollment in Phase 3 YOSEMITE study
homozygous familial hypercholesterolemiasource ↗
▲Topline ReadoutPlozasiranApprovedClinical Data
Topline results from SHASTA-3 study of plozasiran in severe hypertriglyceridemia
severe hypertriglyceridemiasource ↗
▲Primary Endpoint MetPlozasiranApprovedClinical Data
SHASTA-3 met primary endpoint of triglyceride reduction
severe hypertriglyceridemiasource ↗
▲FDA ApprovalPlozasiranApprovedFDA Decision
Regulatory approval as REDEMPLO in multiple geographies
familial chylomicronemia syndromesource ↗
▲Grant / FundingCorporate
Board approved inducement grants of up to 112,794 restricted stock units to 95 new employees
▲Topline ReadoutPlozasiranApprovedClinical Data
Arrowhead reported topline data from Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in sHTG
severe hypertriglyceridemiasource ↗
▲Product LaunchREDEMPLOApprovedPost-Market
U.S. REDEMPLO launch continued to build momentum during fiscal Q3
familial chylomicronemia syndrome (FCS)source ↗
▲Reimbursement / PricingREDEMPLOApprovedPost-Market
Favorable policies in place for most significant U.S. payers for REDEMPLO
familial chylomicronemia syndrome (FCS)source ↗
▲EU ApprovalREDEMPLOApprovedEx-US Regulatory
EC approval of REDEMPLO (plozasiran) for FCS
Familial Chylomicronemia Syndrome (FCS)source ↗
●Oral PresentationPresentation
Arrowhead to host webinar on cardiometabolic pipeline as part of 2026 Summer Series of R&D Webinars
cardiometabolicsource ↗
◆Oral PresentationPresentation
Arrowhead Pharmaceuticals to participate in upcoming June 2026 events
◆Trial CompletionPlozasiranApprovedTrial
Completion of SHASTA-3 Phase 3 study
severe hypertriglyceridemiasource ↗
▲EU ApprovalREDEMPLOApprovedEx-US Regulatory
European Commission marketing authorization for REDEMPLO (plozasiran)
familial chylomicronaemia syndrome (FCS)source ↗
◆Oral PresentationARO-INHBEPresentation
Presentation of new clinical data on ARO-INHBE at EASL 2026
obesity and MASHsource ↗
▲Oral PresentationPresentation
Presentation of new positive clinical cardiometabolic data at 94th EAS Congress
cardiometabolicsource ↗
▲FDA ApprovalREDEMPLOApprovedFDA Decision
REDEMPLO (plozasiran) FDA approval for FCS
Familial Chylomicronemia Syndrome (FCS)source ↗
▲CHMP Positive OpinionREDEMPLOApprovedEx-US Regulatory
Positive CHMP opinion for REDEMPLO in Europe
familial chylomicronemia syndromesource ↗
▲NMPA NDA ApprovalREDEMPLOApprovedEx-US Regulatory
NMPA approval of REDEMPLO in China
familial chylomicronemia syndromesource ↗
▲Other Regulator MilestoneREDEMPLOApprovedEx-US Regulatory
Health Canada NOC for REDEMPLO
familial chylomicronemia syndromesource ↗
▲Oral PresentationPlozasiranApprovedPresentation
Long-term efficacy and safety data presented at ACC 2026
hypertriglyceridemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How ARWR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-06 | ARO-ALK7 | Phase 1/2a interim results | Phase 1/2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B71 / 100
Pipeline Score
$6.8B
Pipeline Value
$2.9B
Commercial Value
Fair Value
Valuation Signal
25
Drugs Scored
1.1x
rNPV / MCap
Top 4%
Small Cap(rank 27 of 658)
Percentile Rank
Arrowhead Pharmaceuticals, Inc. holds a solid B-grade pipeline (71/100), with $10.5B risk-adjusted pipeline value, led by ARO-RAGE in Asthma (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-Q), to Jun 2026) Revenue $669.5M x 4.4 = $2.9B
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ARO-RAGE Small moleculeNCT05276570 | Asthma | Phase 2 | COMPLETED | 206 | Apr 16, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARWR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| plozasiran BreakthroughPriorityFast Track+1 | severe hypertriglyceridemia | Phase 3 | 2026-08-30 | significant reductions in triglyceride levelsRead More | Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe HypertriglyceridemiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PERRY MICHAEL SDirector | Sell | -11,600 111,459 held | $87.30 | 08/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARWR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.3 % (25.8 %) | 925.59 M | 11.36 M | 6.13% ( 655.56 K) |
ARWR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARWR ranks across every disease it competes in
Competitive Position is a premium feature
See how ARWR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARWR News
ARWR▼ -1.2%today
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals has announced that the FDA has accepted plozasiran into the STAR pilot program. This entry is linked to the company's forthcoming supplemental new drug application for treating severe hypertriglyceridemia, a condition that poses significant health risks. The STAR program aims to enhance the efficiency of the drug review process.
Read more →ARWRArrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Arrowhead Pharmaceuticals has announced a webinar scheduled for October 14, 2026, to discuss interim clinical data from its Phase 1/2a study of ARO-MAPT, aimed at treating Alzheimer's disease and other tauopathies. The event will feature Dr. Adam Boxer from UCSF, emphasizing the company's focus on its central nervous system pipeline.
Read more →ARWR▼ -12.4%on this news
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals has released interim topline data from its Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNAi therapeutic. This treatment aims to address mixed hyperlipidemia associated with atherosclerotic cardiovascular disease by silencing PCSK9 and APOC3. The results indicate a promising advancement in the management of this condition.
Read more →ARWRArrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Arrowhead Pharmaceuticals has announced its participation in several upcoming investor conferences in September 2026. The events include the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference, where the company will present through fireside chats. This engagement highlights Arrowhead's commitment to investor relations and transparency.
Read more →ARWRArrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals presented positive results from its Phase 3 SHASTA-3 and SHASTA-4 studies at the ESC Congress 2026. The studies evaluated plozasiran in adults with severe hypertriglyceridemia and successfully met all primary and secondary endpoints. The findings indicate significant reductions in triglyceride levels, showcasing the drug's potential in managing this condition.
Read more →ARWRArrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Arrowhead Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress in Munich. The presentation will focus on the SHASTA-3 and SHASTA-4 pivotal trial results for Plozasiran in patients with severe hypertriglyceridemia. This event is scheduled for August 30, 2026.
Read more →ARWRPeople Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Arrowhead Pharmaceuticals has announced that REDEMPLO® (plozasiran) is now available in Germany for patients with Familial Chylomicronaemia Syndrome (FCS). This new treatment option, authorized by the European Commission in June 2026, aims to significantly reduce high triglyceride levels in affected individuals. Germany is among the first countries in the EU to offer this therapy.
Read more →ARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals, Inc. reported its fiscal 2026 third quarter results, highlighting significant financial growth and transformational events that bolster future prospects. The company will discuss these results in a conference call scheduled for August 4, 2026. CEO Christopher Anzalone emphasized the positive developments during this period.
Read more →ARWRArrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Arrowhead Pharmaceuticals has acquired a Rare Pediatric Disease Priority Review Voucher from an undisclosed third party. This voucher will be used for the Supplemental New Drug Application for plozasiran, which aims to expand its approved indication for pediatric patients. The submission is expected before the end of 2026.
Read more →ARWRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals announced inducement grants for 95 new employees, approved by the Board of Directors under NASDAQ Rule 5635(c)(4). The grants, totaling up to 112,794 restricted stock units, are designed to incentivize new hires and are outside the company's existing equity incentive plans. This move highlights the company's commitment to expanding its workforce.
Read more →ARWRArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals has successfully completed enrollment in its global Phase 3 YOSEMITE study for zodasiran, aimed at treating homozygous familial hypercholesterolemia (HoFH). This investigational RNA interference therapeutic targets a rare genetic disorder that causes high LDL cholesterol levels and early cardiovascular disease. The completion of enrollment marks a significant milestone in the development of this treatment.
Read more →ARWR▲ +19%on this newsshared move
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran, demonstrating significant triglyceride reduction in patients with severe hypertriglyceridemia. This condition poses a high risk of acute pancreatitis, making effective treatment crucial. The studies successfully met their primary endpoint, indicating the drug's potential efficacy.
Read more →ARWRArrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals has announced a webcast and conference call to discuss its fiscal 2026 third quarter results, scheduled for August 4, 2026. The event will take place at 4:30 p.m. ET and will be accessible via the company's website. A replay will be available shortly after the live event.
Read more →ARWRArrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals has announced that it has received marketing authorization in the European Union for its drug REDEMPLO® (plozasiran). This medication is specifically designed to reduce triglyceride levels in adults suffering from Familial Chylomicronemia Syndrome (FCS). The approval marks a significant milestone for the company in addressing this rare condition.
Read more →ARWRArrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals is set to host a webinar focusing on its cardiometabolic pipeline. This event is part of the 2026 Summer Series of R&D webinars. Details regarding the specific topics or speakers were not provided in the announcement.
Read more →ARWR▼ -5.8%on this news
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals has announced its participation in events scheduled for June 2026. However, the article lacks specific details about the events or the company's agenda. This announcement may indicate the company's ongoing engagement with the industry, but further information is needed to assess its significance.
Read more →ARWRArrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals has presented new clinical data on its RNAi-based candidate ARO-INHBE targeting obesity and MASH at the EASL 2026 conference. The details of the data and its implications for treatment were not disclosed in the provided text.
Read more →ARWRArrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals presented new positive clinical data related to cardiometabolic health at the 94th European Atherosclerosis Society Congress. This data highlights the company's ongoing commitment to addressing cardiovascular diseases. The presentation at such a significant event underscores the potential impact of their findings on future treatment strategies.
Read more →ARWRArrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals has reported its fiscal 2026 second quarter results. The article provides insights into the company's financial performance and operational updates for the period. However, specific details regarding revenue, expenses, or future outlook are not included in the provided text.
Read more →About Arrowhead Pharmaceuticals, Inc.
Headquarters177 E COLORADO BLVD, PASADENA, CA, 91105
Founded1989
BIOPHARMAWATCH ELITE PLUS
Trade the next ARWR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime